Journal of Psychopharmacology
October 8, 2026
Gianluca A. Florineth, Anna L. Boeker, Tobias Bracht et al.
Background: Psilocybin-assisted therapy (PAT) has emerged as a promising intervention for alcohol use disorder (AUD), yet contemporary clinical evidence has not been systematically synthesized to validate its clinical utility and safety profile. Methods: Contemporary clinical trials of PAT for AUD were identified systematically from PubMed, PsycINFO, and Scopus by two independent reviewers....
Therapeutic Advances in Psychopharmacology
October 8, 2026
Gianluca A. Florineth, Anna L. Boeker, Felix Müller et al.
Background Classic psychedelics show potential for treating psychiatric disorders, yet the psychological framework of psychedelic-assisted therapy (PAT) remains underspecified. As regulatory approval approaches, defining the contribution of psychological interventions to clinical outcomes is critical for both mechanism inference and implementation. Objectives To systematically review the...
JAMA Network Open
January 2, 2026
Gianluca Andri Florineth, Isabell Klima, Anna Laura Boeker et al.
5 citations
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessions. Quantitative evidence on how this concomitant therapy contributes to treatment outcomes is limited, highlighting the need for a systematic synthesis. To evaluate whether the quantity of psychological therapy is associated with symptom reduction...
Therapeutische Umschau
April 1, 2025
Tobias Bracht, Daniela Hubl, Kristina Adorjan et al.
1 citation
Depression is one of the most common mental disorders. The effectiveness of pharmacological and psychotherapeutic treatments is well documented. Remission rates are around 67 % for pharmacological antidepressant initial and secondary treatment of a depressive episode in unipolar disorders. However, patients with a depressive episode who do not respond to at least two successive attempts at...
Frontiers in Psychiatry
July 6, 2023
Niklaus Denier, Leila M. Soravia, Franz Moggi et al.
Background: Increased mindfulness is associated with reduced alcohol consumption in patients with alcohol use disorder (AUD) after residential treatment. However, the underlying neurobiological mechanism of mindfulness in AUD is unclear. Therefore, we investigate the structural and functional alterations of the thalamocortical system with a focus on the mediodorsal thalamic nucleus (MD-TN), the...
PLoS One
September 10, 2013
Niklaus Denier, Hana Gerber, Marc Vogel et al.
32 citations
Heroin dependence is a chronic relapsing brain disorder, characterized by the compulsion to seek and use heroin. Heroin itself has a strong potential to produce subjective experiences characterized by intense euphoria, relaxation and release from craving. The neurofunctional foundations of these perceived effects are not well known. In this study, we have used pharmacological magnetic resonance...
Current Topics in Medicinal Chemistry
2012
M Walter, Niklaus Denier, M Vogel et al.
Schizophrenia is a major mental illness that is characterized by psychosis, social withdrawal, and cognitive impairment. High comorbidity rates with substance use disorders have consistently been found - especially with abuse of cannabis and psychostimulants. While the role of these drugs in the onset of psychosis and schizophrenia has received much attention, relatively few studies have been...
Current Pharmaceutical Design
2012
Niklaus Denier, Marc Walter, Kerstin Bendfeldt et al.
We conducted a systematic review on resting state cerebral blood flow activities found in first-episode psychosis (FEP) and during acute effects of cannabinoids and opioids, mental states that can be profoundly different from normal functioning. The main goal was to identify connections of cerebral blood flow measure and regional brain activity patterns associated with subjective experiences...